


PHARMACEUTICAL 2023



Neoleukin Therapeutics Inc. Rank 150 of 446





PHARMACEUTICAL 2023



Neoleukin Therapeutics Inc. Rank 150 of 446

The relative strengths and weaknesses of Neoleukin Therapeutics Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Neoleukin Therapeutics Inc. compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 62% points. The greatest weakness of Neoleukin Therapeutics Inc. is the variable Research and Development, reducing the Economic Capital Ratio by 20% points.

The company's Economic Capital Ratio, given in the ranking table, is 152%, being 109% points above the market average of 43%.

Input Variable	Value in 1000 USD
Assets, Current	99,134
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	11,062
Liabilities, Non-Current	10,322
Other Assets	16,814
Other Compr. Net Income	-21
Other Expenses	0
Other Liabilities	233
Other Net Income	1,540
Other Revenues	0
Property and Equipment	0
Research and Development	41,129
Selling, General and Administrative Expense	17,968

Output Variable	Value in 1000 USD
Assets	115,948
Liabilities	21,617
Expenses	59,097
Revenues	0
Stockholders Equity	94,331
Net Income	-57,557
Comprehensive Net Income	-57,568
Economic Capital Ratio	152%

